United Therapeutics CORP Form 4 insider transactions

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales on June 5, 2026, under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

EVP and General Counsel Paul A. Mahon exercised 8,300 stock options and sold the resulting shares under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., has sold 1,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged trading plan.

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond executed a Rule 10b5-1 trading plan, resulting in the sale of 10,000 shares of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock on May 26, 2026.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales totaling 9,500 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. reports that EVP & General Counsel Paul A. Mahon executed a pre-arranged 10b5-1 plan, involving the exercise of stock options and sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock, including option exercises and sales under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt executed a scheduled sale of 9,500 shares following an option exercise under a Rule 10b5-1 trading plan.

CFO James Edgemond exercised options and sold 10,000 shares of United Therapeutics under a pre-arranged trading plan.